-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network Market Analysis: The new Drug Administration Law encourages the State to take effective measures to encourage the development and innovation of medicines for children, supports the development of new varieties, dosage forms and specifications of children's medicines in line with children's physiological characteristics, and gives priority review and approval to children's medicinesFollowing the introduction of the newly amended Drug Administration Act on 1 December 2019, new news of the bill has recently emerged in the field of children's drug useIt is reported that the relevant departments of the state have started the study of children's drug use legislation, and will carry out a nationwide legislative feasibility survey, widely solicit the views of all sectors of society, accelerate the work of children's drug use legislation
Children, like those with rare diseases, used to be 'vulnerable groups in the drug population.' The industry said that because of limited coverage, research and development costs are too high, low return on investment and other factors, children's medicine and rare drugs are both the pharmaceutical industry's "cold stove." But in recent years, with the promotion of favorable policies, children's medicine "cold stove" is expected to be "hot" by the policy
Six A-share children's drug companies recently released their 2019 annual reports, according to the report, children's drug revenue is risingFor example, in 2019, Guangzhou Baiyunshan only seven-star tea particles a children's drug product operating income reached 158 million yuan, operating income increased 8.61 percent over the previous yearJichuan Pharmaceuticals' 2019 operating income for pediatric drugs was RMB1,524,909,591.71, an increase of 22.42 percent over the previous year
In addition to the increase in revenue from children's medicines, some companies say they have further enriched the product layout of children's healthAs China Resources said, in addition to confirming the company's main business coverage of pediatrics, the 2019 annual report, in the reporting period, the company also basically completed the acquisition of 100% of Theonpharma, further enriching the product layout in the field of children's healthIn addition, 2 varieties, such as the oral solution, were included in the health insurance catalogueDayin pharmaceutical technology innovation ability is constantly strengthened, to children's clinical needs-oriented, adhere to technological innovation, research and development work actively and steadily promote, in 2019 to obtain oral liquid salt dispersion, montiline scattered two products of the production of batch, the company's children's medicine product line is more abundant
It is understood that due to the existence of children's drugs development cycle is long, low profit, high cost, drug evaluation difficulties, and so on, pharmaceutical companies lack the initiative to develop and invest in the enthusiasmIn addition, the particularity of children's groups makes it difficult to develop medicines for childrenTherefore, the lack of children's special drugs has become an old problem in the field of medicine in China, "drug by stoic, dose by guessing", the problem of special drugs is always bothering parents
"At present, the domestic production of children's medicine smaller pharmaceutical factories, children's special drugs far less than adult drugs, mainly some cold drugs and vitamin drugs, most of the drugs used for serious specialist diseases do not have children's dosage forms, children patients face the 'no drug available' dilemma"Some people in the industry say
In order to solve the shortage of children's medicine, there are suggestions in the industry, we need to further strengthen the policy level of children's special drug research and development and production guidance and encouragement, explore research and development of children's drug input, compensation mechanism, improve the relevant laws and regulationsThe author was informed that in recent years, China's children's drug development has also been introduced good news, such as the new "drug management law" to encourage the state to take effective measures to encourage the development and innovation of children's medicines have effectively promoted the development of China's children's drug market
If recently, pharmaceutical companies said that in the next 3 to 5 years, the company will further research and development, production, marketing resources focused on the "children's medicine strategy", consolidate the advantages and hope to expand the leading edgeIt said that for the country's "base drug policy, women's policy, low-cost drug policy" and other favorable policies, it is conducive to the company's leading gold single product further growth, such as "children's lung fever cough asthma oral liquid / particles", "children's chai Gui heat particles" into the national health insurance, national drug directory; Liver care "low-cost drugs and the national base drug catalog, both to help the secondary growth of leading varieties, drug listing license holder policy is also conducive to the company's product approval, production resources integration, and further play the advantages of scale to reduce costs